Skip to main content
PMC home page
Gut logoLink to Gut
. 1996;38(Suppl 2):S48–S55. doi: 10.1136/gut.38.suppl_2.s48

Hepatitis B and hepatitis delta virus infection in South America.

J R Torres 1
PMCID: PMC1398044  PMID: 8786054

Abstract

About 100,000 cases of acute hepatitis B virus (HBV) infection occur annually in South America. The overall prevalence of HBV infection in low risk populations ranges from 6.7% to 41%, while hepatitis B surface antigen (HBsAg) rates range from 0.4% to 13%. In high endemicity aboriginal or rural populations, perinatal transmission may play a major part in the spread of HBV. In urban populations, however, horizontal transmission, probably by sexual contact, is the predominant mode of spread, with higher rates of HBV positivity in lower socioeconomic groups. High risk populations such as health care workers and haemodialysis patients show higher rates of HBV infection than comparable populations elsewhere. The risk of posttransfusion hepatitis B remains high in some areas. Concomitant HBV infection may accelerate the chronic liver disease seen in decompensated hepatosplenic schistosomiasis. In the north, the prevalence of hepatitis delta virus (HDV) infection ranks among the highest in the world. In the south, the problem appears negligible although it is increasing within high risk urban communities. HDV superinfection has been the cause of large outbreaks of fulminant hepatitis. The cost of comprehensive or mass vaccination programmes remains unaffordable for most South American countries. Less expensive alternatives such as low dose intradermal schedules of immunisation have been used with success in selected adult subjects.

Full text

PDF
S51

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arevalo J. A., Washington A. E. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA. 1988 Jan 15;259(3):365–369. [PubMed] [Google Scholar]
  2. Bensabath G., Hadler S. C., Soares M. C., Fields H., Dias L. B., Popper H., Maynard J. E. Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin. JAMA. 1987 Jul 24;258(4):479–483. doi: 10.1001/jama.1987.03400040077025. [DOI] [PubMed] [Google Scholar]
  3. Bensabath G., Hadler S. C., Soares M. C., Fields H., Maynard J. E. Epidemiologic and serologic studies of acute viral hepatitis in Brazil's Amazon Basin. Bull Pan Am Health Organ. 1987;21(1):16–27. [PubMed] [Google Scholar]
  4. Buitrago B., Popper H., Hadler S. C., Thung S. N., Gerber M. A., Purcell R. H., Maynard J. E. Specific histologic features of Santa Marta hepatitis: a severe form of hepatitis delta-virus infection in northern South America. Hepatology. 1986 Nov-Dec;6(6):1285–1291. doi: 10.1002/hep.1840060610. [DOI] [PubMed] [Google Scholar]
  5. Cabezas C., Gotuzzo E., Escamilla J., Phillips I. Prevalencia de marcadores serológicos de hepatitis viral A, B y delta en escolares aparentemente sanos de Huanta (Perú). Rev Gastroenterol Peru. 1994 May-Aug;14(2):123–134. [PubMed] [Google Scholar]
  6. Carrilho F. J., Queiroz M. L., da Silva L. C., da Fonseca L. E., Granato C., Oba I., Obara L. Active immunization against hepatitis B virus (HBV) with low-doses of plasma-derived vaccine by intradermal route. Rev Inst Med Trop Sao Paulo. 1989 Mar-Apr;31(2):91–94. doi: 10.1590/s0036-46651989000200005. [DOI] [PubMed] [Google Scholar]
  7. Carrilho F. J., Queiróz M. L., da Fonseca L. E., Obara L., da Silva L. C. Active immunization against hepatitis B virus (HBV) with low-doses of plasma-derived vaccine by intradermal route. Anti HBs response after 3 years of follow-up. Rev Inst Med Trop Sao Paulo. 1991 Mar-Apr;33(2):167–167. doi: 10.1590/s0036-46651991000200013. [DOI] [PubMed] [Google Scholar]
  8. Choc de Zanalda B., Manterola A. C., Díaz Lestrem M., Frider B., Zocchi G. A., Fainboim H., Clua G. I., Amor E. Prevalencia del anticuerpo contra el antígeno central del virus de la hepatitis B (anti-HBc) en personal hospitalario de Buenos Aires. Bol Oficina Sanit Panam. 1990 Jan;108(1):16–26. [PubMed] [Google Scholar]
  9. Clements C. J., Kane M., Hu D. J., Kim-farley R. La vacuna contra la hepatitis B: un nuevo frente contra las enfermedades pandemicas. Foro Mund Salud. 1990;11(2):165–168. [PubMed] [Google Scholar]
  10. Colichón A., Vildósola H., Sjögren M., Cantella R., Safary A. Respuesta serológica a una vacuna DNA recombinante en nativos residentes de dos áreas hiperendémicas a hepatitis B en la Amazonía Peruana. Rev Gastroenterol Peru. 1993 May-Aug;13(2):78–84. [PubMed] [Google Scholar]
  11. Farfán G., Vidal J., Phillips I., Llerena S. Marcadores serológicos de hepatitis viral B en pacientes drogadictos del Hospital Hermilio Valdizán. Rev Gastroenterol Peru. 1989;9(2):95–99. [PubMed] [Google Scholar]
  12. Fay O. H. Hepatitis B in Latin America: epidemiological patterns and eradication strategy. The Latin American Regional Study Group. Vaccine. 1990 Mar;8 (Suppl):S100–S139. [PubMed] [Google Scholar]
  13. Fernández Barboza R., Rivero D., Echeverría B., Machado I. V. Costo-beneficio de la vacunación contra la hepatitis B en trabajadores de hospitales de Venezuela. Bol Oficina Sanit Panam. 1991 Jul;111(1):16–23. [PubMed] [Google Scholar]
  14. Fonseca J. C., Simonetti S. R., Schatzmayr H. G., Castejón M. J., Cesário A. L., Simonetti J. P. Prevalence of infection with hepatitis delta virus (HDV) among carriers of hepatitis B surface antigen in Amazonas State, Brazil. Trans R Soc Trop Med Hyg. 1988;82(3):469–471. doi: 10.1016/0035-9203(88)90166-6. [DOI] [PubMed] [Google Scholar]
  15. Garrison M. W., Baker D. E. Therapeutic advances in the prevention of hepatitis B: yeast-derived recombinant hepatitis B vaccines. DICP. 1991 Jun;25(6):617–627. doi: 10.1177/106002809102500611. [DOI] [PubMed] [Google Scholar]
  16. Gayotto L. C. Hepatitis delta in South America and especially in the Amazon region. Prog Clin Biol Res. 1991;364:123–135. [PubMed] [Google Scholar]
  17. Hackett J. Salmonella-based vaccines. Vaccine. 1990 Feb;8(1):5–11. doi: 10.1016/0264-410x(90)90169-m. [DOI] [PubMed] [Google Scholar]
  18. Hadler S. C., Alcala de Monzon M., Bensabath G., Martinez Duran M., Schatz G., Fields H. A. Epidemiology of hepatitis delta virus infection in less developed countries. Prog Clin Biol Res. 1991;364:21–31. [PubMed] [Google Scholar]
  19. Hadler S. C., Fay O. H., Pinheiro F., Maynard J. E. La hepatitis en las Américas: informe del grupo colaborador de la OPS. Bol Oficina Sanit Panam. 1987 Sep;103(3):185–209. [PubMed] [Google Scholar]
  20. Hoofnagle J. H. Chronic hepatitis B. N Engl J Med. 1990 Aug 2;323(5):337–339. doi: 10.1056/NEJM199008023230510. [DOI] [PubMed] [Google Scholar]
  21. Koziol D. E., Holland P. V., Alling D. W., Melpolder J. C., Solomon R. E., Purcell R. H., Hudson L. M., Shoup F. J., Krakauer H., Alter H. J. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med. 1986 Apr;104(4):488–495. doi: 10.7326/0003-4819-104-4-488. [DOI] [PubMed] [Google Scholar]
  22. Lahaye D., Strauss P., Baleux C., van Ganse W. Cost-benefit analysis of hepatitis-B vaccination. Lancet. 1987 Aug 22;2(8556):441–443. doi: 10.1016/s0140-6736(87)90971-8. [DOI] [PubMed] [Google Scholar]
  23. Machado Bártoli I. A propósito de políticas nacionales de salud en relación con hepatitis viral. Informes presentados en Mayo 1985 y Septiembre 1986 ante la Organización Panamericana de la Salud OPS/OMS. G E N. 1986 Oct-Dec;40(4):217–222. [PubMed] [Google Scholar]
  24. Machado I. V., Deibis L., Risquez E., Tassinari P., Zabaleta M. E., Toro F. I., Baroja M. L., Corado J., Ruiz M. E., Longart L. Abordaje inmunoclinico, molecular e inmunopatológico de la hepatitis crónica viral. Consideraciones terapeuticas. G E N. 1994 Jul-Sep;48(3):124–132. [PubMed] [Google Scholar]
  25. Machado I. V., Deibis L., Zabaleta M., Toro F. I., Marino V., Ramirez J. L., DePerez F. E., Bianco N. E. Assessment of delta virus infection in Venezuelan high-risk population for hepatitis B virus. Prog Clin Biol Res. 1991;364:105–113. [PubMed] [Google Scholar]
  26. Machado I. V. Inmunobiología del virus de la hepatitis B. G E N. 1991 Oct-Dec;45(4):315–328. [PubMed] [Google Scholar]
  27. Machado I., de Marcano N. B., Rosales A., Rincon R., Carvajal J., Rivero M. T., Muñoz J. F., Flores M. E., Flores J. L., Chinea M. Riesgo de exposición ocupacional al virus de la hepatitis B en personal de salud Venezolano. Estudio multicéntrico. G E N. 1990 Jan-Mar;44(1):1–8. [PubMed] [Google Scholar]
  28. Machado I., de Monzón M., Fernández R., Mondolfi A., Hernández J. R., Vetencourt R., Golindano C., Garassini M., Grases P., Jr, Hadler S. Hepatitis B virus: a public health problem in Venezuela. Bull Pan Am Health Organ. 1985;19(2):176–181. [PubMed] [Google Scholar]
  29. Mazzur S., Nath N., Fang C., Bastiaans M. J., Molinaris J. L., Balcaser M., Beker S., Brunings E. A., Cameron A. R., Farrel V. Distribución de marcadores de virus de hepatitis B (VHB) en la sangre de donadores de 13 paises del hemisferio occidental: actas del Taller Latinoamericano de la Cruz Roja sobre Hepatitis B. Bol Oficina Sanit Panam. 1980 Sep;89(3):239–248. [PubMed] [Google Scholar]
  30. Muller G. Y., Zabaleta M. E., Arminio A., Colmenares C. J., Capriles F. I., Bianco N. E., Machado I. V. Risk factors for dialysis-associated hepatitis C in Venezuela. Kidney Int. 1992 Apr;41(4):1055–1058. doi: 10.1038/ki.1992.160. [DOI] [PubMed] [Google Scholar]
  31. Méndez M., Arce M., Kruger H., Sánchez S. Prevalencia de marcadores serológicos de hepatitis vírica en diversos grupos de población del Peru. Bol Oficina Sanit Panam. 1989 Feb;106(2):127–138. [PubMed] [Google Scholar]
  32. Pereira L. M., Melo M. C., Lacerda C., Spinelli V., Domingues A. L., Massarolo P., Mies S., Saleh M. G., McFarlane I. G., Williams R. Hepatitis B virus infection in schistosomiasis mansoni. J Med Virol. 1994 Feb;42(2):203–206. doi: 10.1002/jmv.1890420219. [DOI] [PubMed] [Google Scholar]
  33. Pinho J. R., Santos C. A., Gonzalez C. L., Bassit L., Barreto C. C., Saez-Alquezar A., França A. V., Carrilho F. J., Fonseca L. E., Chamone D. A. Detection of hepatitis B virus DNA by the polymerase chain reaction in anti-HBe positive chronic hepatitis B patients. Rev Inst Med Trop Sao Paulo. 1993 Nov-Dec;35(6):515–520. doi: 10.1590/s0036-46651993000600007. [DOI] [PubMed] [Google Scholar]
  34. Popper H., Thung S. N., Gerber M. A., Hadler S. C., de Monzon M., Ponzetto A., Anzola E., Rivera D., Mondolfi A., Bracho A. Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology. 1983 Nov-Dec;3(6):906–912. doi: 10.1002/hep.1840030603. [DOI] [PubMed] [Google Scholar]
  35. Pujol F. H., Rodríguez I., Martínez N., Borberg C., Favorov M. O., Fields H. A., Liprandi F. Viral hepatitis serological markers among pregnant women in Caracas, Venezuela: implication for perinatal transmission of hepatitis B and C. G E N. 1994 Jan-Mar;48(1):25–28. [PubMed] [Google Scholar]
  36. Rizzetto M., Ponzetto A., Forzani I. Epidemiology of hepatitis delta virus: overview. Prog Clin Biol Res. 1991;364:1–20. [PubMed] [Google Scholar]
  37. Seijas L. F., Montilla Y., Zabaleta M., Vargas E., Gabriel M. L., Mujica C., Mazzara M. N., Hernández Alvarez G. Determinación de alfa feto proteína en pacientes infectados con virus B y C. Comunicación preliminar. G E N. 1993 Apr-Jun;47(2):65–69. [PubMed] [Google Scholar]
  38. Sjogren M. H., Colichon A. Hepatitis B and delta hepatitis infection in Peru. Prog Clin Biol Res. 1991;364:97–104. [PubMed] [Google Scholar]
  39. Torres J. R., Machado I. V. Special aspects of hepatitis B virus and delta virus infection in Latin America. Infect Dis Clin North Am. 1994 Mar;8(1):13–27. [PubMed] [Google Scholar]
  40. Torres J. R., Mondolfi A. Protracted outbreak of severe delta hepatitis: experience in an isolated Amerindian population of the Upper Orinoco basin. Rev Infect Dis. 1991 Jan-Feb;13(1):52–55. doi: 10.1093/clinids/13.1.52. [DOI] [PubMed] [Google Scholar]
  41. Torres J. R., de Marquez M. L., Gonzalez A., Ramirez V., Martinez N., Lecuna V. Eficacia comparativa de las vías intradérmica e intramuscular en la inmunización activa contra la hepatitis B con una vacuna recombinante. Resultados preliminares. G E N. 1993 Jul-Sep;47(3):145–149. [PubMed] [Google Scholar]
  42. Valladares Alvarez G., Galarza J., Espinoza J., Nieri A., Makino R., Berrocal A., Grados N. Determinación de marcadores serológicos del virus de la hepatitis B en áreas de alto riesgo del Hospital Central Fuerza Aérea del Perú. Rev Gastroenterol Peru. 1989;9(1):13–16. [PubMed] [Google Scholar]
  43. Velasco M., De la Fuente C. Estudio del antígeno de superficie de la hepatitis B en 489 prostitutas de Santiago. Rev Med Chil. 1983 May;111(5):461–462. [PubMed] [Google Scholar]
  44. Vetencourt Rojas R., Suárez Isea A., Boada Boada J. J., Oropeza F., de Armas J. Estudio clínico y epidemiológico de 256 casos de hepatitis viral aguda. G E N. 1984 Jan-Jun;38(1-2):1–11. [PubMed] [Google Scholar]
  45. Zabaleta M. E., Toro F. I., Ruiz M. E., Colmenares C. J., Bianco N. E., Machado I. V. Assessment of former and newly developed HBV assays in a Third World setting. J Med Virol. 1992 Dec;38(4):240–245. doi: 10.1002/jmv.1890380403. [DOI] [PubMed] [Google Scholar]
  46. da Fonseca J. C., Ferreira L. C., Brasil L. M., Castilho M. da C., Moss R., Barone M. Fulminant Labrea hepatitis--the role of hepatitis A (HAV), B (HBV), C (HCV), and D (HDV) infection. (Preliminary report). Rev Inst Med Trop Sao Paulo. 1992 Nov-Dec;34(6):609–612. doi: 10.1590/s0036-46651992000600017. [DOI] [PubMed] [Google Scholar]
  47. de Fonseca J. C., Gayotto L. C., Ferreira L. C., Araújo J. R., Alecrim W. D., Santos R. T., Simonetti J. P., Alves V. A. Labrea hepatitis--hepatitis B and delta antigen expression in liver tissue: report of three autopsy cases. Rev Inst Med Trop Sao Paulo. 1985 Jul-Aug;27(4):224–227. doi: 10.1590/s0036-46651985000400011. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES